## Abstract CEP‐18770, [(1__R__)‐1‐{[(2__S__,3__R__)‐3‐hydroxy‐2‐{[(6‐phenyl‐2‐pyridinyl)carbonyl]amino}butanoyl]amino}‐3‐methylbutyl]boronic acid, is a novel proteasome inhibitor, now under early clinical evaluation as an anticancer agent. To investigate its clinical pharmacokinetics, a high‐perfo
✦ LIBER ✦
Development of high performance liquid chromatography tandem mass spectrometric methods for the determination of a novel ascomycin-based immunoregulant in human whole blood and plasma: A case of potential analyte loss during sample collection
✍ Scribed by I. Fu; E. J. Woolf; B. Karanam; S. Vincent; B. K. Matuszewski
- Publisher
- Springer
- Year
- 2002
- Tongue
- English
- Weight
- 675 KB
- Volume
- 55
- Category
- Article
- ISSN
- 0009-5893
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
Development and validation of a high-per
✍
Federica Sala; Elena Marangon; Renzo Bagnati; Valeria Livi; Roberta Cereda; Maur
📂
Article
📅
2010
🏛
John Wiley and Sons
🌐
English
⚖ 149 KB
Development and validation of a high-per
✍
Federica Sala; Renzo Bagnati; Valeria Livi; Roberta Cereda; Maurizio D'Incalci;
📂
Article
📅
2011
🏛
John Wiley and Sons
🌐
English
⚖ 195 KB
E‐3810, 6‐[[7‐[(1‐aminocyclopropyl)methoxy]‐6‐methoxy‐4‐quinolyl]oxy]‐__N__‐methyl‐naphthalene‐1‐carboxamide, is a novel, potent, dual inhibitor of vascular endothelial growth factor and fibroblast growth factor receptors with antiangiogenic properties, now under early clinical evaluation as an anti